WISeKey reveals Class B share election results ahead of merger

WISeKey International Holding Ltd (SIX: WIHN; NASDAQ: WKEY) announced the results of its Class B share election process related to its proposed cross-border merger with its British Virgin Islands subsidiary, according to a press release dated September 25, 2026.

The BVI subsidiary, formerly known as WISeKey International Corp., changed its name to WISeQey Corp. effective September 16, 2026. WISeQey will be the surviving entity in the merger.

The election period for holders of WISeKey Class B registered shares closed on September 23, 2026. Eligible holders could elect to receive either one WISeQey ordinary share for each WISeKey Class B share held, or ten WISeQey Class B shares for each WISeKey Class B share held, subject to a Class B share cap and related allocation mechanics. Holders who did not make a valid election will receive one WISeQey ordinary share per WISeKey Class B share.

Based on the final results, holders of 518 WISeKey Class B shares elected to receive WISeQey Class B shares. Upon completion of the merger, WISeQey expects to issue:

• 5,180 WISeQey Class B shares for valid elections by WISeKey Class B shareholders


• 4,176,654 WISeQey ordinary shares for remaining WISeKey Class B shares, including those represented by American Depositary Shares


• 1,819,060 WISeQey Class F shares in exchange for outstanding WISeKey Class A shares

WISeKey shareholders approved the merger at an Extraordinary General Meeting held on September 9, 2026. Completion of the merger remains subject to satisfaction of remaining closing conditions and applicable Swiss and BVI corporate, regulatory, and administrative procedures.

WISeKey stated it will provide further updates on the effective date of the merger and the commencement of trading of WISeQey ordinary shares on Nasdaq and SIX Swiss Exchange once remaining conditions and implementation steps are completed.

You May Also Be Interested In

• Workday prices $2.5 billion senior notes offering across four tranches
• Oculis reports biomarker data from Phase 2 trial of Privosegtor
• Cognizant agrees to buy DyFlex Solutions to expand SAP reach in ANZ